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Primary aldosteronism is the most common cause of secondary hypertension. In the past, screening for primary aldosteronism
was oﬀered only in patients with hypertension associated with hypokalemia. Recent studies showed that hypokalemia is seen in
only 25% of the patients with primary aldosteronism,which has increased the prevalence of primary aldosteronism to 10–15% of
all cases with new onset hypertension.
1.Introduction
Approximately 85 million people in the United States are
estimated to be hypertensive. In the majority, the hyperten-
sion is “essential” or “idiopathic,” but a subgroup of approx-
imately 15% has secondary hypertension. The secondary
causes of hypertension can be divided into renal (e.g., reno-
vascularorrenal parenchymal disease)andendocrinecauses.
There are at least 14 endocrine disorders in which hyperten-
sion may be the initial clinical presentation (Table 1).
A further classiﬁcation of the adrenocortical causes of
hypertension based on the levels of renin and aldosterone
can be used for the diagnostic approach of a patient with
suspected endocrine hypertension (Table 2).
An accurate diagnosis of endocrine hypertension pro-
vides the clinician with a unique treatment opportunity, that
is, to render a surgical cure or to achieve a dramatic response
with pharmacologic therapy. Primary hyperaldosteronism,
which represents the most common cause of endocrine
resistant hypertension, is reviewed here.
2.AldosteroneBiosynthesis and
Controlof Secretion
The diﬀerentiation of the adrenal cortex into distinct zones
has important functional consequences. The zona glomeru-
losa comprises approximately 15% of the cortex (depending
upon sodium intake). Cells are clustered in spherical nests
and are small with smaller nuclei in comparison to other
zones. The zona fasciculata comprises the 75% of the
cortex; in this zone, the cells are large and lipid laden and
form radial cords between the ﬁbrovascular radial network.
The innermost zona reticularis is sharply demarcated from
both zona fasciculata and the adrenal medulla; cells are
irregular with little lipid content. Three main types of
hormone are producedbytheadrenal cortex-glucocorticoids
(cortisol, corticosterone), mineralocorticoids (aldosterone,
deoxycorticosterone), and sex steroids (mainly androgens).
Aldosterone is synthesized from cholesterol in a series
of six biosynthetic steps [1] .T h eﬁ r s tf o u rs t e p sa r ea l s o
involved in the synthesis of cortisol, whereas the last two
pertain only to aldosterone [2]. The product of the CYP11B2
gene is capable of catalyzing both the 11-hydroxylase and
18-hydroxylaseand18-hydroxydehydrogenasestepsinaldos-
terone biosynthesis [2–4]. The CYP11B2 gene is located on
human chromosome 8q24.3-tel [5].
Aldosterone, the major circulating mineralocorticoid,
is a steroid hormone produced exclusively in the zona
glomerulosa. The major regulators of aldosterone biosyn-
thesis and secretion are the renin-angiotensin system and
potassium ion concentrations. Minor regulators include
corticotrophin (ACTH) from the pituitary, atrial natri-
uretic peptide from the heart, and dopamine secreted
locally in the adrenal. A number of aldosterone precursors,2 International Journal of Hypertension
Table 1: Endocrine causes of hypertension.
Adrenal dependent
(1)Pheochromocytoma
(2)Cushing’s syndrome
(3)Primary hyperaldosteronism
(4)Other adrenocortical tumors (i.e., carcinoma, other)
(5)Genetic defects aﬀecting adrenocortical function
(i) Congenital adrenal hyperplasia: 11β-Hydroxylase and 17α-Hydroxylase deﬁciency, primarily
(ii) Primary cortisol resistance
Apparent mineralocorticoid excess (AME)/11β-Hydroxysteroid dehydrogenase deﬁciency
Genetic
(i) Type 1 AME
(ii) Type 2 AME
Acquired
(i) Licorice or carbenoxolone ingestion (type 1 AME)
(ii) Cushing’s syndrome (type 2 AME)
Thyroid dependent
Hyperthyroidism
Parathyroid dependent
Hyperparathyroidism
Pituitary dependent
(1) Acromegaly
(2) Cushing’s disease
Table 2: Adrenocortical causes of hypertension.
Low renin and high aldosterone
Primary aldosteronism
(1) Aldosterone producing adenomas(APA)—35%of cases
(2) Bilateral idiopathic hyperplasia(IHA)—60% of cases
(3) Primary adrenal hyperplasia—2% of cases
(4) Aldosterone-producing adrenocortical carcinoma—<1% of cases
(5) Familial Hyperaldosteronism(FH)
(i) Glucocorticoid-remediable Aldosteronism(FH type I)—<1% of cases
(ii) FH type II(APA or IHA)—<2% of cases
(6) Ectopic aldosterone producing adenoma or carcinoma—<0.1%of cases
Low renin and low aldosterone
Hyperdeoxycorticosteronism
(1) Congenital adrenal hyperplasia
11β-hydroxylase deﬁciency
17α-hydroxylase deﬁciency
(2) Deoxycorticosterone producing tumor
(3) Primary cortisol resistance
(4) Apparent mineralocorticoid excess (AME) 11β-Hydroxysteroid dehydrogenase deﬁciency (Genetic or Acquired)
(5) Cushing’s syndrome and Cushing’s disease
including deoxycorticosterone and 18-hydroxycorticostero-
ne, have mineralocorticoid activity, and their hypersecretion
in various pathological states may produce orexacerbate fea-
tures typical of mineralocorticoid hypertension. Aldosterone
actsmainly onthe distalnephronalthoughseveralothersites
of sodium reabsorption exist.
The classic functions of aldosterone are regulation of
extracellular volume and control of potassium homeostasis.
These eﬀects are mediated by binding of free aldosterone to
the mineralocorticoid receptor in the cytosol of epithelial
cells principally in the kidney. Mineralocorticoid receptors
have a tissue-speciﬁc expression. For example, tissues withInternational Journal of Hypertension 3
the highest concentration of these receptors are the distal
nephron, hippocampus, and colon. Lower concentrations
are found in the rest of the gastrointestinal tract and heart.
Transport to the nucleus and binding to speciﬁc binding
domainson targetedgenesleadto theirincreased expression.
Aldosterone-regulated kinase appears to be a key interme-
diary, and its increased expression leads to modiﬁcation of
the apical sodium channel, resulting in increased sodium
ion transport across the cell membrane. The increased
tubular negativity augments tubular secretion of potassium
by the tubular cells and hydrogen ion by the interstitial
cells.
Glucocorticoids and mineralocorticoids bind equally
to the mineralocorticoid receptor. Speciﬁcity of action is
provided by the presence of a glucocorticoid metaboliz-
ing enzyme, 11β-hydroxysteroid dehydrogenase (11BHSD2),
which metabolizes cortisol to cortisone and prevents gluco-
corticoids from interacting with the receptor.
In addition to the classic genomic actions mediated by
aldosterone binding to cytosolic receptors, mineralocorti-
coids have acute, nongenomic actions due to activation of
an unidentiﬁed cell surface receptor. This action involves
most likely a G protein-coupled receptor and probably a
modiﬁcation of the sodium hydrogen exchange activity.
Aldosterone has additional, nonclassic eﬀects primarily
on non epithelial cells. These include the expression of
several collagen genes, genes controlling tissue growth fac-
tors, such as transforming growth factor β and plasminogen
activator inhibitor type 1, and genes mediating inﬂamma-
tion. The resultant actions lead to microangiopathy, necrosis
(acutely),and ﬁbrosis in various tissues such as the heart, the
vasculature, and the kidney.
At the level of the zona glomerulosa, the major stim-
ulatory inﬂuences are angiotensin II and serum potassium
[6, 7]. ACTH stimulates aldosterone secretion in an acute
but transient fashion, but it is questionable whether ACTH
plays a signiﬁcant role in the chronic regulation of miner-
alocorticoid secretion [8]. The major inhibitory inﬂuences
aﬀecting the zona glomerulosa are exerted by circulating
atrial natriureticpeptide(ANP)andlocallybydopamine[9].
Although ANPlevels are clearly increased in hyperaldostero-
nism, neither ANP nor dopamine has been implicated as
primary causes of clinically signiﬁcant defects in aldosterone
secretion. Metoclopramide increases aldosterone secretion,
suggesting dopamine may inhibit aldosterone release [10–
12]. The physiologic roles of adrenomedullin and vasoactive
intestinal peptide (VIP) on aldosterone secretion remain to
be clariﬁed; it appears that both these neuropeptides are
produced in the rat zona glomerulosa [13, 14].
3.PrimaryHyperaldosteronism
In his presidential address at the Annual Meeting of the Cen-
tral Society for Clinical research, Chicago Illinois, October
29 1954, Dr. Jerome W. Conn stated: “I have prepared no
comprehensive review of my personal philosophy of clinical
investigation. Instead, I plan to make a scientiﬁc report to
youabout a clinical syndrome, the investigation ofwhich has
been most exciting to me since I initiated it in April of this
year”.
InApril1954,ConnwasaskedtoseeM.W.,a34-year-old
woman with a 7-year history of muscle spasms, temporary
paralysis, tetany, and weakness and a 4-year history of
hypertension. Because there were no signs or symptoms of
glucocorticoid or androgen excess, Conn suspected based on
his prior research that M. W.’s clinical presentation could
result from excess secretion of the adrenal salt-retaining
corticoid. Conn planned for a bilateral adrenalectomy on
December 1954. In 1955, Gittler and Fajans told of the
surgical scene: To “the immense delight of Conn and those
in the operating room, the surgeon, Dr. William Baum,
encountered a right 13gr adrenal tumor which was removed
while leaving the contralateral gland intact. The patient’s
post operative studies showed an almost total reversal of the
preoperative metabolic and clinical abnormalities”.
By 1964, Conn had collected 145 cases, and he suggested
that up to 20% of patients with essential hypertension
might have primary aldosteronism. Later, Conn decreased
his predicted prevalence or primary aldosteronism to 10%
of hypertensives, a prediction that was substantiated nearly
40 years later.
In the past, clinicians would not consider the diagnosis
of primary hyperaldosteronism unless the patient presented
with spontaneous hypokalemia, and then the diagnostic
evaluation would require discontinuation of antihyperten-
sive medications for at least 2 weeks. The spontaneous
hypokalemia/no antihypertensive drug approach resulted in
predicted prevalence rates of less than 0.5% of hypertensive
patients.
However, it is now recognized that most patients with
primary aldosteronism are not hypokalemic and that screen-
ing can be completedwith a simple blood test (plasma aldos-
terone concentration[PAC]-to-plasma renin activity (PRA)
ratio) while the patient is taking antihypertensive drugs.
Using the PAC/PRA ratio as a screening test, followed by
conﬁrmatory testing, has resulted in much higher prevalence
estimates (5% to 13% of all patients with hypertension) for
primary aldosteronism.
Since Conn described the ﬁrst case of an aldosterone-
producing adenoma, several subtypes of primary aldos-
teronism have been described (Table 2). The diﬀerential
diagnosis of these subtypes is crucial for the management
and the prognosis.
4.ClinicalPresentation
The diagnosis of primary aldosteronism is usually made
in patients who are in the third to sixth decade of life.
In cases associated with hypokalemia, patients may have
muscle spasms, weakness, headaches, palpitations, polyuria,
polydipsia, nocturia, or a combination of these. Periodic
paralysis is a very rare presentation in Caucasians but not an
infrequent presentation in patients of Asian descent. Some-
times, tetany can develop due to decreased ionized calcium
from hypokalemic alkalosis. The nocturia and polyuria are
a result of hypokalemia-induced renal concentrating defect,4 International Journal of Hypertension
and the presentation is frequently mistaken for prostatic
disease in men.
There are no speciﬁc physical ﬁndings. Edema is not a
common ﬁnding because of the mineralocorticoid escape
phenomenon. The degree of hypertension may be moderate
to severe and may be resistant to usual pharmacologic
treatments. Patient with aldosterone producing adenoma
tend to have higher blood pressure compared to patient with
bilateral idiopathic hyperplasia. Hypokalemia is frequently
absent; in some patients, the hypokalemia can become evi-
dent only with the addition of potassium-wasting diuretics,
and some patients can develop profound hypokalemia with
only small doses of diuretics. Because of a reset osmostat,
the serum sodium concentration tends to be high normal
or above the upper limit of normal. This clinical clue is
very useful when initially assessing the potential for primary
aldosteronism.
Patients with primary aldosteronism may be at higher
riskthanotherpatientswithessentialorsecondaryhyperten-
sion for target-organ damage of the heart and kidney. That
can be explained from a direct eﬀect of aldosterone on these
organs.
5.ScreeningforPrimaryAldosteronism
The diagnostic approach to primary aldosteronism can be
consideredinthreephases:screening,conﬁrmation,followed
by subtype evaluation tests.
Physicians should always consider screening for primary
aldosteronism in the following situations:
(1) hypertension and hypokalemia,
(2) resistant hypertension,
(3) adrenal incidentaloma and hypertension,
(4) onset of hypertension at a young age (<20 years),
(5) severe hypertension (>160mm systolic or >100 dias-
tolic),
(6) secondary hypertension,
(7) profoundhypokalemiawithusualdosesofpotassium
wasting diuretics.
The initial screening tests include the measurement of
plasma aldosterone concentration and plasma renin activity
and calculation of the PAC/PRA (ARR) ratio. Like all
biochemical case detection tests, the ARR is not without
false positives and negatives. Table 2 documents the eﬀect of
medications and conditions on the ARR. The ARR should,
therefore, be regarded as a detection test only and should be
repeated if the initial results are inconclusive or diﬃcult to
interpret because of suboptimal sampling conditions.
If a patient is already on any of the medications listed in
Table 3, he can be switched over to medications [15, 16]t h a t
donotaﬀectoraﬀectminimallytheARR.InTable 4 arelisted
the antihypertensive medications that have minimal eﬀects
on plasma aldosterone levels and can be used to control
hypertension during case ﬁnding and conﬁrmatory testing
for primary aldosteronism [15, 16].
Table 3
PAC PRA PAC/PRA
Medications
β-Adrenergic blockers ↓↓ ↓↑ (FP)
Central α-2 agonists ↓↓ ↓↑ (FP)
NSAIDs ↓↓ ↓↑ (FP)
K+-wasting diuretics →↑ ↑↑ ↓(FN)
K+-sparing diuretics ↑↑ ↑↓ (FN)
ACE inhibitors ↓↑ ↑↓ (FN)
ARBs ↓↑ ↑↓ (FN)
Ca2+ blockers (DHPs) →↓ ↑ ↓(FN)
Renin inhibitors ↓↓ ↑ 1 ↑(FP)1
↓ (FN)1
Potassiumstatus
Hypokalemia ↓→ ↑↓ (FN)
Potassiumloading ↑→ ↓↑ (FP)
Dietary sodium
Sodium restricted ↑↑ ↑↓ (FN)
Sodium loaded ↓↓ ↓↑ (FP)
Advancing age ↓↓ ↓↑ (FP)
Other conditions
Renal impairment →↓ ↑ (FP)
PHA-2 →↓ ↑ (FP)
Pregnancy ↑↑ ↑↓ (FN)
Renovascular HTN ↑↑ ↑↓ (FN)
Malignant HTN ↑↑ ↑↓ (FN)
The ARR is most sensitive when used in patients from
whom samples are collected in the morning after patients
have been out of bed for at least 2h, usually after they have
been seated for 5–15min and without posture stimulation.
Ideally, patients should have unrestricted dietary salt intake
before testing. In many cases, the ARR can be conﬁdently
interpreted with knowledge of the eﬀect on the ARR of
continued medications or suboptimal conditions of testing,
avoidingdelayand allowing thepatient toproceed directlyto
conﬁrmatory/exclusion testing [15, 16]. Washout ofall inter-
fering antihypertensive medications is feasible in patients
with mild hypertension but is potentially problematic in
others and perhaps unnecessary in that medications with
minimal eﬀect on the ARR can be used in their place
(Table 4).
A suggested approach [15, 16] for measurement of ARR
as per the 2008 Endocrine Society guidelines follow.
(A) Preparation for ARR Measurement: Agenda
(1) Attempt to correct hypokalemia, after measuring
plasma potassium in blood collected slowly with a
syringe and needle (preferably not a Vacutainer to
minimize the risk of spuriously raising potassium);
avoid ﬁst clenching during collection; wait at least
5sec after tourniquet release (if used to achieve
insertion of needle); ensure separation of plasma
from cells within 30min of collection.International Journal of Hypertension 5
Table 4
Drug Class Usual dose Comments
Verapamil slow release
Nondihydropyridine
calcium channel
antagonist
90–120mg twice daily
Use singly or in combination
with the other agents listed in
this table.
Hydralazine Vasodilator 10–12.5mg twice daily,
increasing as required
Commence verapamil slow
release ﬁrst to prevent reﬂex
tachycardia. Commencement at
low doses reduces risk of side
eﬀects (including headaches,
ﬂushing, and palpitations).
Prazosinhydrochloride α-Adrenergic blocker
0.5–1mg two to three
times daily, increasing as
required
Monitor for postural
hypotension
Doxazosin mesylate α-Adrenergic blocker 1–2mg once daily,
increasing as required
Monitor for postural
hypotension
Terazosin hydrochloride α-Adrenergic blocker 1–2mg once daily,
increasing as required
Monitor for postural
hypotension
(2) Encourage patient to liberalize (rather than restrict)
sodium intake.
(3) Withdraw agents that markedly aﬀect the ARR (48)
for at least 4 weeks:
(a) spironolactone, eplerenone, amiloride, and tri-
amtereneb,
(b) potassium-wasting diureticsc,
(c) products derived from licorice root (e.g., con-
fectionary licorice, chewing tobacco).
(4) If the results of ARR of the above agents are not diag-
nostic, and if hypertension can be controlled with
relatively noninterfering medications (see Table 4),
withdraw other medications that may aﬀect the ARR
(48) for at least 2 weeks like
(a) β-Adrenergic blockers, central α-2 agonists
(e.g., clonidine and α-methyldopa), nons-
teroidal anti-inﬂammatory drugs,
(b) angiotensin-converting enzyme inhibitors, an-
giotensin receptor blockers, renin inhibitors,
and dihydropyridine calcium channel antago-
nists.
(5) If necessary to maintain hypertension control, com-
mence other antihypertensive medications that have
lesser eﬀects on the ARR (e.g., verapamil slow
release, hydralazine (with verapamil slow release, to
avoid reﬂex tachycardia), prazosin, doxazosin, and
terazosin; see Table 4).
(6) Establish OC and HRT status, because estrogen-
containing medications may lower DRC and cause
false-positive ARR when DRC (rather than PRA) is
measured. Do not withdraw OC unless conﬁdent of
alternative eﬀective contraception.
(B) Conditions for Collection of Blood
(1) Collect blood mid-morning, after the patient has
been up (sitting, standing, or walking) for at least 2h
and seated for 5–15min.
(2) Collect blood carefully, avoiding stasis and hemolysis
(see A.1 above).
(3) Maintain sample at room temperature (and not on
ice, because this will promote conversion of inactive
to active renin) during delivery to laboratory and
before centrifugation and rapid freezing of plasma
component pending assay.
(C) Factors to Take into Account when Interpreting Results
(see Table 3)
(1) Age: in patients aged >65 yr, renin can be lowered
more than aldosterone by age alone, leading to a
raised ARR.
(2) Time of day, recent diet, posture, and length of time
in that posture.
(3) Medications.
(4) Method of blood collection, including any diﬃculty
doing so.
(5) Level of potassium.
Level of creatinine (renal failure can lead to false-positive
ARR).
Another important consideration when we are screening
patients for primary aldosteronism is the reliability and
the sensitivity of the assay we use for both aldosterone
and plasma renin activity. Because the ARR is mathe-
matically highly dependent on renin, renin assays should
be suﬃciently sensitive to measure levels as low as 0.2–
0.3ng/mL·h (DRC 2mU/liter). Although most laboratories
use radioimmunoassay (RIA) for plasma and urinary aldos-
terone, measured levels of standards have been shown to6 International Journal of Hypertension
be unacceptably diﬀerent in some instances. Tandem mass
spectrometry is increasingly used and has proved to be much
more consistent in performance.
6.InterpretationofARR
Secondary hyperaldosteronism should be considered when
both PRA and PAC are increased and the ARR is less
than 10 (e.g., Renovascular disease). If both PAC and PRA
are suppressed, an alternate source of mineralocorticoid
receptor agonist should be considered (e.g., hypercorti-
solism). Primary aldosteronism should be suspected when
PRA is suppressed (<1ng/mL/hr) and PAC is increased. It
is important to understand that the lower limit of detection
varies among diﬀerent PRA assays and can have dramatic
eﬀect on the PAC/PRA ratio. For example, if the lower
limit for detection of for PRA is 0.6ng/mL/hr and the PAC
is 16ng/dL, then the ARR would be 27. However, if the
lower limit for detection of PRA is 0.1ng/mL/hr, then the
ARR would be 160. Thus, the ARR cutoﬀ for a high ARR
is laboratory dependent and more speciﬁcally PRA assay
dependent.
In a retrospective study [17], the combination of an
ARR>30 and PAC >20ng/dL had a sensitivity of 90% and
a speciﬁcity of 91% for aldosterone producing adenomas. At
Mayo clinic, an ARR of more than 20 and a PAC >15ng/dL
are found in more than 90% of patients with surgically
conﬁrmed aldosterone producing adenomas.
M o s tg r o u p s ,h o w e v e r ,u s ec u t o ﬀs of 20–40 when testing
is performed in the morning on a seated ambulatory patient.
Some investigators [18] require elevatedaldosterone levelsin
addition to elevated ARR for a positive screening test for PA
(usually aldosterone >15ng/dL.) An alternative approach is
to avoid a formal cutoﬀ level for plasma aldosterone but to
recognize that thelikelihood ofa false-positive ARRbecomes
greater when renin levels are very low.
Against a formal cutoﬀ level for aldosterone are the
ﬁndings of several studies. In one study, seated plasma aldos-
terone levels were less than 15ng/d in 36% of 74 patients
diagnosed with PA afterscreening positive by ARRdeﬁned as
more than 30 and showing failure of aldosterone to suppress
duringﬂudrocortisone suppressiontesting (FST)and infour
of 21 patients found by AVS to have unilateral, surgically
correctable PA. Another study reported plasma aldosterone
levels of 9–16ng/dL in 16 of 37 patients diagnosed with PA
by FST. Although it would clearly be desirable to provide
ﬁrm recommendations for ARR and plasma aldosterone
cutoﬀs, the variability of assays between laboratories and the
divided literature to date makes it more prudent to point out
relative advantages and disadvantages, leaving clinicians the
ﬂexibility to judge for themselves.
7.ConﬁrmatoryTests
An increased ARR is not diagnostic by itself and con-
ﬁrmatory tests are required to demonstrate inappropriate
aldosterone secretion. Treatment with spironolactone or
eplerenone should not be started before the conﬁrmation
of primary aldosteronism. In patients already receiving
treatment with spironolactone or eplerenone, the treatment
should be held for at least 4–6 weeks before further
diagnostic testing. Aldosterone suppression testing can be
performed with orally administered sodium chloride and
measurement of urinary aldosterone or with intravenous
sodium chloride loading and measurement of PAC.
8.OralSodiumLoadingTest
After hypertension and hypokalemia are controlled, patients
should increase their sodium intake to >200mmol/d
(∼6g/d) for 3d, veriﬁed by 24-h urine sodium content.
Patients should receive adequate slow-release potassium
chloride supplementation to maintain plasma potassium in
thenormal range.Urinary aldosteroneismeasured in the24-
h urine collection from the morning of d 3 to the morning of
d 4. Primary aldosteronism is unlikely if urinary aldosterone
is lower than 10μg/24h (27.7nmol/d) in the absence of
renal disease, where primary aldosteronism may coexist with
lower measured urinary aldosterone levels. Elevated urinary
aldosterone excretion (>12μg/24h (>33.3nmol/d) at the
Mayo Clinic, >14μg/24h (38.8nmol/d) at the Cleveland
Clinic) makes primary aldosteronism highly likely. This test
shouldnotbeperformedinpatientswithsevereuncontrolled
hypertension, renal insuﬃciency, cardiac insuﬃciency, car-
diac arrhythmia, or severe hypokalemia. The 24-h urine
collection may be inconvenient. Laboratory-speciﬁc poor
performance of the RIA for urinary aldosterone (aldosterone
18-oxo-glucuronide or acid-labile metabolite) may blunt
diagnostic accuracy, a problem obviated by the currently
available HPLC-tandem mass spectrometry methodology.
Aldosterone18-oxo-glucuronideisarenalmetabolite,andits
excretion may not rise in patients with renal disease.
9.IntravenousSalineInfusionTest
The test is done after an overnight fast. Patients stay in the
recumbent position for at least 1h before and during the
infusion of2litersof0.9%saline ivover4h, starting at0800–
0930h. Blood samples for renin, aldosterone, cortisol, and
plasma potassium are drawn at time zero and after 4h, with
blood pressure and heart rate monitored throughout the
test. Postinfusion plasma aldosterone levels <5ng/dLmake
the diagnosis of primary aldosterone unlikely, and levels
>10ng/dL are a very probable sign of primary aldosterone.
Values between 5 and 10ng/dL are indeterminate and can
be seen in patients with bilateral idiopathic hyperplasia.
This test should not be performed in patients with severe
uncontrolled hypertension, renal insuﬃciency,cardiac insuf-
ﬁciency, cardiac arrhythmia, or severe hypokalemia.
10.SubtypeStudies
All patients with primary aldosteronism (PA) should
undergo an adrenal CT scan as the initial study in sub-
type testing and to exclude large masses that may rep-
resent adrenocortical carcinoma. The ﬁndings on adrenalInternational Journal of Hypertension 7
CT—normal-appearing adrenals, unilateral macroadenoma
(>1cm), minimal unilateral adrenal limb thickening, uni-
lateral microadenomas (≤1cm), or bilateral macro- or
microadenomas (or a combination of the two)—are used
in conjunction with adrenal venous sampling (AVS) and,
if needed, ancillary tests to guide treatment decisions in
patients with PA. Aldosterone-producing adenomas (APA)
may be visualized as small hypodense nodules (usually
<2cm in diameter) on CT. Adrenal glands with bilat-
eral idiopathic hyperplasia (IHA) may be normal on CT
or show nodular changes. Aldosterone-producing adrenal
carcinomas are almost always more than 4cm in diam-
eter, but occasionally smaller, and like most adrenocorti-
cal carcinomas have a suspicious imaging phenotype on
CT.
Adrenal CT has several limitations. Small APAs may
be interpreted incorrectly by the radiologist as IHA on
the basis of CT ﬁndings of bilateral nodularity or normal-
appearing adrenals. Moreover, apparent adrenal microade-
nomas may actually represent areas of hyperplasia, and uni-
lateral adrenalectomy would be inappropriate. In addition,
nonfunctioning unilateral adrenal macroadenomas are not
uncommon, especially in older patients (>40yr) and are
indistinguishable from APAs on CT. Unilateral UAH may be
visibleonCT,ortheUAHadrenal mayappearnormalonCT.
Magnetic resonance imaging has no advantage over CT in
subtype evaluation of PA, being more expensive and having
less resolution than CT.
11.AdrenalVenousSampling
Lateralization of the source of the excessive aldosterone
secretion is critical to guide the management of PA.
Distinguishing between unilateral and bilateral disease is
important because unilateral adrenalectomy in patients with
APA or UAH results in normalization of hypokalemia in
all; hypertension is improved in all and cured in 30%–
60% [19, 20] .I nb i l a t e r a lI H Aa n dG R A ,u n i l a t e r a lo r
bilateral adrenalectomy seldom corrects the hypertension,
and medical therapy is the treatment of choice. Unilateral
disease may be treated medically if the patient declines or is
not a candidate for surgery.
Adrenal vein sampling was initially proposed as a way to
localize catecholamine secreting neoplasms (Young 2009).In
1967, Melby et al. reported the use of adrenal vein sampling
in primary aldosteronism, and it has since become the gold
standard test to diﬀerentiate unilateral from bilateral disease
(Young 2009). In his initial paper, he reported the compar-
ison of aldosterone from the right and left adrenal veins in
seven patients with primary aldosteronism and also in three
normal patients. The authors found elevated aldosterone
secretion and a higher aldosterone to cortisol ratio from the
involved adrenal gland compared to the uninvolved adrenal
gland. All primary aldosteronism patients in the study were
operated for unilateral adrenalectomy and were found to
have adenomas that correlated with the lateralization found
on adrenal vein sampling (Melby 1967).
From this ﬁrst report, adrenal vein sampling in primary
aldosteronism has continued to evolve. Some controversies
remain including whether the addition of cosyntropin to
the test either as a bolus or constant infusion improves
the diagnostic accuracy and what diagnostic criteria to use
(Auchus2010).In performing this test, there are some things
that need to be considered. First, the patient needs to be
prepared properly. They should be tested in a fasting state
and be supine for at least one hour before testing (Young
2009). Additionally, certain antihypertensives should be
avoided to prevent false results. Mineralocorticoid receptor
antagonists in particular should be discontinued at least 6
weeksbeforetesting.Preferred medicationsincludeextended
release verapamil, α-adrenergic blockers, and hydralazine.
Patients should also be potassium repleted as hypokalemia
can lower the aldosterone levels (Rossi 2007).
In addition to patient preparation, the test should
be performed by an experienced and skilled practitioner,
especially given some of the technical diﬃculties that can
arise in cannulating the right adrenal vein. Additionally,
a well-deﬁned protocol should be in place (Rossi 2007,
Young 2009). Samples are obtained from the right adrenal,
left adrenal, and from a peripheral source. This should be
performed simultaneously or in rapid sequence to limit
ﬂuctuations in secretion that occur with time (Young 2009).
The NIH protocol for adrenal vein sampling in primary
aldosteronism is as follows.
(1) Catheterization of bilateral femoral veins is per-
formed with a 0.45 polyurethane catheter with 6
French sheath in the right, and Muller catheter in the
left.
(2) Cannulation of both adrenal veins is obtained via the
right femoral vein.
(3) Simultaneous baseline sampling for aldosterone and
cortisol is performed from both adrenal veins, and
a peripheral sample is drawn from the left femoral
catheter at time −5 minutes and at time 0 minutes.
(4) After obtaining baseline samples, a 0.25mg push of
ACTH is given followed by steady infusion of ACTH
of 1mcg/ml at 150–200ml/hr.
(5) At time +10 minutes and +15 minutes, simultaneous
samples are again obtained from right adrenal vein,
left adrenal vein, and left femoral vein.
(6) Upon completion of sampling, ACTH infusion is
stopped and switched to normal saline at KVO, and
catheters are removed.
It is important to note that all samples are stored on ice
during sampling and are then transported to the laboratory
on ice for processing.
Interpretation of the results of the sampling is dependent
notonlyonthealdosteroneconcentrationandonthecortisol
concentration but also on whether ACTH stimulation was
used. In thesetting ofACTHstimulation during adrenal vein
sampling, a few ratios need to be calculated. The ﬁrst is the
selectivity index (SI) which is used to determine if there was
adequate cannulation of the adrenal veins. This is calculated8 International Journal of Hypertension
Table 5
Location Aldosterone Cortisol Selectivity index A:C ratio
Right adrenal A D D/F A/D
Left adrenal B E E/F B/E
Peripheral C F
by taking the ratio of cortisol from the adrenal compared
to the cortisol from the peripheral sample. This should be
done for both right and left sided samples. With ACTH
stimulation, a ratio of 5:1 indicates successful cannulation
of the adrenal vein. Without ACTH stimulation, a ratio of
3:1 suggestssuccessful cannulationthough diﬀerentcut-oﬀs
have been suggested (Young 2009).
After conﬁrming successful cannulation, the next step
is to determine unilaterality versus bilaterality. First, the
aldosterone concentration needs to be corrected for possible
dilution by dividing by the cortisol to get the A: C ratio.
Next, the cortisol corrected values are compared to calculate
the lateralization index (LI). The greater of A: C ratio is
divided by the smaller A:C ratio. A ratio of >4:1 suggests
lateralization, <3:1 suggests bilateral disease, and anything
in between is inconclusive (Young 2009, Auchus 2010). An
example of the calculation follows Table 5.
In this example, selectivity index (SI) should be >5
to indicate successful cannulation of the adrenal veins.
Lateralization index (LI) would be calculated by taking the
higher A:C ratio divided by the lower A:C ratio. If LI is
> 4, then unilateraldisease lateralizingtothenumerator side
is suggested. If LI is <3, then bilateral disease is suggested.
If LI is between 3 and 4, then the results are indeterminate
and a repeat study may need to be considered. Alternatively,
repeating the assay on samples stored from the test or
measuring 18-hydroxycorticosterone could be considered
(Auchus2010). The true sensitivity and speciﬁcity of the test
is diﬃcult to determine, as calculating this would require
performing an adrenalectomy on all patients to verify the
diagnosis.
12.Treatment
Unilateral laparoscopic adrenalectomy should be oﬀered to
patients with documented unilateral PA (i.e., APA or UAH).
Ifapatientisunableorunwillingtoundergosurgery,medical
treatment with a mineralocorticoid receptor antagonist is
recommended. Hypertension is cured (deﬁned as blood
pressure <140/90mmHgwithouttheaid ofantihypertensive
drugs)inabout50%(range,35%–60%)ofpatientswithAPA
after unilateral adrenalectomy, with a cure rate as high as
56%–77% when the cure threshold was blood pressure less
than 160/95mm Hg.
There are two mineralocorticoid receptor antagonists
that can be used for the management of patients with pri-
mary hyperaldosteronism: spironolactone and eplerenone.
Usually, a low dose of either antagonist can signiﬁcantly and
eﬀectively improve hypokalemia, but for the management of
hypertension, high doses are required. In patients intolerant
to mineralocorticoid receptor antagonists, dihydropyridine
calcium channel blockers such as nifedipine can be used
alternatively, since studies have been shown that it directly
inhibits the synthesis of aldosterone and blocks the miner-
alocorticoid receptors.
Factors associated with resolution of hypertension in
the postoperative period include having one or no ﬁrst-
degree relative with hypertension and preoperative use of
two or fewer antihypertensive drugs. Other factors have
been reported to predict cure but have been evaluated
by only univariate analysis or when the cutoﬀ for blood
pressure resolution was less than 160/95mmHg, duration
of hypertension less than 5yr, higher PAC to PRA ratio
preoperatively, higher urinary aldosterone secretion, or
positive preoperative response to spironolactone. The most
common reasons for persistently increased blood pressure
after adrenalectomy are coexistent hypertension of unknown
cause and older age and/or longer duration of hypertension.
13.Pre- and PostoperativeManagement
In the patient scheduled for surgery, both hypertension
and hypokalemia should be well controlled preoperatively.
Obtaining such control may require a delay in surgery and
the addition of a mineralocorticoid receptor antagonist.
Plasma aldosterone and renin activity levels should be
measured shortly after surgery as an early indication of
biochemicalresponse,andonpostoperativeday1,potassium
supplementation should be withdrawn, spironolactone dis-
continued, and antihypertensive therapy reduced, if appro-
priate.
Postoperative iv ﬂuids should be normal saline without
potassium chloride unless serum potassium levels remain
very low (i.e., <3.0mmol/liter), and during the ﬁrst few
weeks after surgery, a generous sodium diet should be
recommended to avoid the hyperkalemia that can develop
fromhypoaldosteronismduetochroniccontralateraladrenal
gland suppression. In rare instances, temporary ﬂudrocorti-
sone therapy may be required.
Blood pressure typically normalizes or shows maximal
improvement in 1–6 months after unilateral adrenalectomy
for unilateral APA but can continue to fall for up to 1yr in
some patients.
14.FamilialFormsofPrimaryAldosteronism
Glucocorticoid-remediable aldosteronism (GRA), also
known as familial hyperaldosteronism type I (FH I), is a
monogenic formofinherited hypertension, ﬁrst describedin
1966by Sutherlandetal. (1966).This disease ischaracterized
by high plasma aldosterone levels, suppressed plasma renin
activity, and abnormally high production of two rare
steroids: 18-hydroxycortisol (18OHF) and 18-oxocortisol
(18oxoF). The synthesis of these steroids requires the
simultaneous presence of a 17-hydroxylase activity and the
two C18 (18-hydroxylase and 18-oxidase) activities typical
of the CYP11B2 (aldosterone synthase) enzyme.
In GRA, the secretion of aldosterone is primarily regu-
lated by adrenocorticotropic hormone (ACTH) rather thanInternational Journal of Hypertension 9
angiotensin II; in fact, the symptoms are exacerbated by
ACTH administration and normalized by glucocorticoid
administration. Despite the state of hyperaldosteronism,
hypokalemia is not a common feature. In aﬀected families,
there is an increased frequency of early death from stroke
and an increased risk for exacerbation of hypertension
during pregnancy. However, the majority of aﬀected family
members has mild-to-moderate hypertension and normal
biochemistry and isclinicallyindistinguishable from patients
with essential hypertension. It is, therefore, possible that
this condition is under diagnosed. This monogenic form
of hypertension is noteworthy, because it is frequently
unresponsive to standard antihypertensive medication but
successfully managed by treatment with amiloride, spirono-
lactone, or dexamethasone alone.
The GRA is inherited in an autosomal dominant fashion
and is caused by the presence of a chimeric gene origi-
nating from an unequal crossover between the CYP11B1
(11 -hydroxylase) and CYP11B2 genes. The hybrid gene
has the CYP11B1 sequence at the 5
  end, including the
promoter, and the CYP11B2 sequence at the 3
  end. The
CYP11B1 promoter ensures the expression of the hybrid
gene throughout the adrenal cortex, whereas the CYP11B2
sequence leads to the inappropriate synthesis of aldosterone,
18OHF, and 18oxoF. The exact position of the crossover
site, occurring between intron 2 and exon 4, does not
seem to aﬀect the phenotype. Aldosterone suppression by
dexamethasone, and high 18OHF and 18oxoF levels are
used to diﬀerentiate glucocorticoid-remediable aldostero-
nism from the other forms of primary aldosteronism.
Deﬁnitive diagnosis can only be reached by identiﬁcation
of the CYP11B1/CYP11B2 chimeric gene in genomic DNA
using either Southern blotting or the long PCR tech-
nique.
FH-II is an inherited, nonglucocorticoid remediable
form of hyperaldosteronism that was relatively recently
recognized as a distinct entity. The onset of FH-II occurs
usually in adulthood. Apart from its familial occurrence,
FH-II is clinically, biochemically, and morphologically indis-
tinguishable from apparently nonfamilial primary aldos-
teronism and also overlaps with essential hypertension.
Pathologic aldosterone secretion may result from unilateral
adenoma or bilateral hyperplasia with diﬀerent subtypes
sometimes occurring within diﬀerent members of the same
family. Diagnosis of FH-II can be suspected by documenting
primary aldosteronism in two-to-three members (ideally
two generations) of a family and excluding the CYP11B1/2
gene. Most, but not all patients could be linked to chro-
mosome 7p22, consistent with the hypothesis that FH-II
and maybe primary aldosteronism in general are likely to
be genetically heterogeneous [21,2 1] .S i n c eF H - I Il a c k s
steroid sensitivity, therapeutic options resemble those of
the sporadic forms of primary aldosteronism. Like in FH-
I it is advisable to avoid genomic and nongenomic eﬀects
by removal of the source of aldosterone secretion. Of
course, surgery is only indicated if lateralization can be
demonstrated by adrenal vein sampling. The second-best
approach is blockage of aldosterone eﬀects with receptor
antagonists.
15.Summary
Primary hyperaldosteronism is more frequent in hyper-
tensive subjects than was previously believed. It is now
recognized that the APA is just one of the seven subtypes
of primary aldosteronism. APA and bilateral idiopathic
hyperaldosteronism (IHA) are the most common subtypes
of primary aldosteronism. Using the plasma aldosterone to
plasma renin activity ratio as a case-ﬁnding test, followed by
aldosterone suppressionconﬁrmatory testing, has resultedin
much higher prevalence estimates of 5%–13% of all patients
with hypertension. In patients with suspected primary
aldosteronism, screening can be accomplished by measuring
a morning (preferablybetween0800and 1000h)ambulatory
paired random plasma aldosterone concentration (PAC) and
plasma renin activity (PRA). An increased PAC: PRA ratio
is not diagnostic by itself, and primary aldosteronism must
be conﬁrmed by demonstrating inappropriate aldosterone
secretion. Aldosterone suppression testing can be performed
with orally administered sodium chloride and measurement
of urinary aldosterone or with intravenous sodium chloride
loading and measurement of PAC. Adrenal venous sampling
performed by an experienced interventional radiologist is
the gold standard for the diﬀerentiation between APA and
non-APA-causes of primary aldosteronism. Distinguishing
between unilateral and bilateral adrenal hypersecretion is
critical in assessing treatment options.
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